Ignite Creation Date:
2024-05-06 @ 12:48 AM
Last Modification Date:
2024-10-26 @ 10:55 AM
Study NCT ID:
NCT01660347
Status:
WITHDRAWN
Last Update Posted:
2016-10-21
First Post:
2012-08-05
Brief Title:
Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant
Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University
Organization:
Thomas Jefferson University
Study Overview
Official Title:
Compassionate Use of the CliniMACS CD34 Reagent System for Patients Requiring a Post Hematopoietic Stem Cell Transplant Boost of Donor Hematopoietic Stem Cells
Status:
WITHDRAWN
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Slow accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical trial studies how well donor stem cell boost works in treating patients with low blood cells after donor stem cell transplant Donor stem cell boost may increase low blood cell counts caused by hematologic cancer or its treatment
Detailed Description:
Successful engraftment after allogeneic hematopoietic stem cell transplant HSCT is defined by an actual neutrophil count ANC of 500 106L and a self-sustaining platelet count of 20 x 109L ANC recovery usually occurs 14 to 21 days after the infusion of donor HSCs with red cell and platelet recovery typically following within the same time frame although resolution of anemia may occur last Recovery time is dose dependent but in one report donor HSC aliquots containing 19 to 205 106kg CD34 cells resulted in an ANC of 500 106L at a median of 12 days and 16 days for patients receiving filgrastim versus those not receiving a white cell growth factor In this trial self-sustaining platelet counts of 20 x 109L occurred at median times of 15 to 11 days respectively The results of another trial comparing outcomes between patients receiving mobilized peripheral blood stem cells PBSCs versus those receiving marrow from their donors showed that median times ANC of 500 106L and self-sustaining platelet counts of 20 x 109L were 16 and 13 days respectively in the group receiving PBSCs and 21 and 19 days in those receiving marrow Similar HSC doses associated with successful engraftment in these time frames have been demonstrated in other trials
Most transplant centers require a minimum dose of 1 to 2 x 106 CD34 cellskg to achieve adequate count recovery in a reasonable time frame post HSCT although an early trial examining recovery after autologous reinfusion of HSCs demonstrated that a threshold of 25 x 106kg of CD 34 cells was associated with consistent and rapid WBC and platelet recovery times 18 and 14 days respectively A later trial assessing autologous PBSC mobilization in breast cancer patients showed that HSC doses of 5 x 106 CD34 cellskg were associated with an 85 probability of WBC and platelet recovery by day 14 but with doses of 2 x 106 or less 10 of patients had platelet recovery beyond day 28 While the precise dose of HSCs for successful engraftment in the allogeneic setting is not known patient characteristics such as myelofibrosis andor splenomegaly are likely to cause interpatient variation in the minimum number of HSCs needed for successful engraftment In addition donor factors such as mismatch in size with the recipient and biologic variation in the number of HSCs that can be obtained from any individual donor can create a deficit in the amount of HSCs required for robust count recovery in a particular recipient All of these factors can contribute to a poor functional or numeric cell dose and result in pancytopenia after HSCT
Drugs required for the prophylaxis and treatment of GVHD and infection have myelotoxic effects post HSCT and unlike their use in solid organ transplantation the marrow toxic effects of these drugs are potentially more severe and longer lasting in the presence of a newly reconstituting immune system While many drugs can have negative effects on marrow function after HSCT mycophenolate mofetil MMF and ganciclovir are two of the most commonly used agents with the potential to cause cytopenias
After hydrolysis to its active form mycophenolic acid MPA MMF inhibits T and B cell proliferation making its use valuable in the prevention of graft versus host and host versus graft reactions post HSCT especially in conjunction with a calcineurin inhibitor Levels of MPA are increased in the presence of altered renal function and other commonly used post HSCT drugs including acyclovir ganciclovir valaganciclovir and tacrolimus A major side effect of MMF is pancytopenia particularly neutropenia which is exacerbated by high drug levels Due to finding of a wide interpatient variability in drug exposure it has recently been recommended that the monitoring of MPA levels would result in better therapeutic outcomes although MPA drug levels are not commonly obtained as yet in clinical practice Myelotoxicity from the drug is observed after renal transplantation in the presence of a non-transplanted immune system demonstrating the potent myelosuppression associated with this drug and the increased toxicity in patients with abnormal renal function Patients post HSCT are treated with multiple drugs that both increase MPA levels and alter creatinine clearance and are thereby highly susceptible to the marrow toxic effects of the drug which can result in cytopenias
Ganciclovir and valganciclovir which is rapidly converted to ganciclovir by intestinal mucosal cells and hepatocytes to ganciclovir are inhibitors of DNA synthesis Ganciclovir is a known myelotoxic drug that is effective in prophylaxis and treatment of cytomegalovirus CMV infections in transplant recipients Salzberger et al examined the outcomes between engraftment and day 100 post HSCT of 278 patients receiving ganciclovir and found that 41 of patients receiving the drug had an ANC less than 1000 106L for at least 2 consecutive days Hyperbilirubinemia during the first 20 days after HSCT elevated serum creatinine after day 21 and low marrow cellularity between days 21 and 28 were significant risk factors for neutropenia Patients with 3 risk factors had a 57 chance of developing neutropenia which was significantly associated with a decreased overall and event free survival As noted above concomitant use of ganciclovir and MMF increase the serum concentration of both drugs exacerbating marrow toxicity Because CMV is a life-threatening disease post HSCT it is often necessary to use ganciclovir especially in the presence of renal failure which is exacerbated with the use of foscarnet the alternate drug for CMV treatment Therefore ganciclovir-induced pancytopenia may be unavoidable in certain contexts
Other medications with potentially toxic effects on the marrow alone or in combination with other commonly used agents which may contribute to the development of post HSCT cytopenias include levetiracetam methotrexate antibiotics such as linezolid vancomycin amoxicillin cephalosporins cidofovir and gabapentin
In addition to insufficient allogeneic cell doses and medication toxicities infections post HSCT can also result in persistent cytopenias Reactivation of human herpes virus 6 HHV-6 and CMV in particular are associated with pancytopenia HHV-6 reactivates at a median of 20 days post-HSCT and active infection has been shown in almost 50 of patients The clinical syndrome associated with an active HHV-6 infection varies in intensity and may include encephalitis rash interstitial pneumonitis and secondary graft failure A transient clinically insignificant HHV-6 reactivation occurs in many patients and because the symptoms of an HHV-6 infection are heterogenous and therefore less recognized the disease may become severe prior to the recognition that the reactivation requires treatment HHV-6 can become chronically active and has been associated not only with secondary graft failure but pure red cell aplasia as well
CMV reactivation in the post HSCT period can also be accompanied by an acute syndrome manifested by fever myalgia and suppressed marrow function Leukopenia at the start of CMV therapy has been associated with a poor response to anti-viral therapy and is a risk factor for progression of CMV viremia to CMV disease While the most serious manifestations of CMV disease are related to pulmonary and enteral infections CMV-induced marrow suppression and marrow failure has been described with identification of specific genotypes of CMV highly associated with mortality from pancytopenia Because CMV and the treatment for CMV can both be associated with post HSCT cytopenias it is often difficult to distinguish which of the two is the major etiological factor
Although the pathophysiology is unclear persistent cytopenias post HSCT have also been associated with acute and chronic GVHD bacterial and fungal infections and impaired hepatic and renal function Because failure of hematopoietic recovery after HSCT is associated with compromised patient survival this protocol was developed to provide patients with persistent cytopenias post HSCT a boost of their original donors HSCs to improve peripheral blood counts
Most transplant centers require a minimum dose of 1 to 2 x 106 CD34 cellskg to achieve adequate count recovery in a reasonable time frame post HSCT although an early trial examining recovery after autologous reinfusion of HSCs demonstrated that a threshold of 25 x 106kg of CD 34 cells was associated with consistent and rapid WBC and platelet recovery times 18 and 14 days respectively A later trial assessing autologous PBSC mobilization in breast cancer patients showed that HSC doses of 5 x 106 CD34 cellskg were associated with an 85 probability of WBC and platelet recovery by day 14 but with doses of 2 x 106 or less 10 of patients had platelet recovery beyond day 28 While the precise dose of HSCs for successful engraftment in the allogeneic setting is not known patient characteristics such as myelofibrosis andor splenomegaly are likely to cause interpatient variation in the minimum number of HSCs needed for successful engraftment In addition donor factors such as mismatch in size with the recipient and biologic variation in the number of HSCs that can be obtained from any individual donor can create a deficit in the amount of HSCs required for robust count recovery in a particular recipient All of these factors can contribute to a poor functional or numeric cell dose and result in pancytopenia after HSCT
Drugs required for the prophylaxis and treatment of GVHD and infection have myelotoxic effects post HSCT and unlike their use in solid organ transplantation the marrow toxic effects of these drugs are potentially more severe and longer lasting in the presence of a newly reconstituting immune system While many drugs can have negative effects on marrow function after HSCT mycophenolate mofetil MMF and ganciclovir are two of the most commonly used agents with the potential to cause cytopenias
After hydrolysis to its active form mycophenolic acid MPA MMF inhibits T and B cell proliferation making its use valuable in the prevention of graft versus host and host versus graft reactions post HSCT especially in conjunction with a calcineurin inhibitor Levels of MPA are increased in the presence of altered renal function and other commonly used post HSCT drugs including acyclovir ganciclovir valaganciclovir and tacrolimus A major side effect of MMF is pancytopenia particularly neutropenia which is exacerbated by high drug levels Due to finding of a wide interpatient variability in drug exposure it has recently been recommended that the monitoring of MPA levels would result in better therapeutic outcomes although MPA drug levels are not commonly obtained as yet in clinical practice Myelotoxicity from the drug is observed after renal transplantation in the presence of a non-transplanted immune system demonstrating the potent myelosuppression associated with this drug and the increased toxicity in patients with abnormal renal function Patients post HSCT are treated with multiple drugs that both increase MPA levels and alter creatinine clearance and are thereby highly susceptible to the marrow toxic effects of the drug which can result in cytopenias
Ganciclovir and valganciclovir which is rapidly converted to ganciclovir by intestinal mucosal cells and hepatocytes to ganciclovir are inhibitors of DNA synthesis Ganciclovir is a known myelotoxic drug that is effective in prophylaxis and treatment of cytomegalovirus CMV infections in transplant recipients Salzberger et al examined the outcomes between engraftment and day 100 post HSCT of 278 patients receiving ganciclovir and found that 41 of patients receiving the drug had an ANC less than 1000 106L for at least 2 consecutive days Hyperbilirubinemia during the first 20 days after HSCT elevated serum creatinine after day 21 and low marrow cellularity between days 21 and 28 were significant risk factors for neutropenia Patients with 3 risk factors had a 57 chance of developing neutropenia which was significantly associated with a decreased overall and event free survival As noted above concomitant use of ganciclovir and MMF increase the serum concentration of both drugs exacerbating marrow toxicity Because CMV is a life-threatening disease post HSCT it is often necessary to use ganciclovir especially in the presence of renal failure which is exacerbated with the use of foscarnet the alternate drug for CMV treatment Therefore ganciclovir-induced pancytopenia may be unavoidable in certain contexts
Other medications with potentially toxic effects on the marrow alone or in combination with other commonly used agents which may contribute to the development of post HSCT cytopenias include levetiracetam methotrexate antibiotics such as linezolid vancomycin amoxicillin cephalosporins cidofovir and gabapentin
In addition to insufficient allogeneic cell doses and medication toxicities infections post HSCT can also result in persistent cytopenias Reactivation of human herpes virus 6 HHV-6 and CMV in particular are associated with pancytopenia HHV-6 reactivates at a median of 20 days post-HSCT and active infection has been shown in almost 50 of patients The clinical syndrome associated with an active HHV-6 infection varies in intensity and may include encephalitis rash interstitial pneumonitis and secondary graft failure A transient clinically insignificant HHV-6 reactivation occurs in many patients and because the symptoms of an HHV-6 infection are heterogenous and therefore less recognized the disease may become severe prior to the recognition that the reactivation requires treatment HHV-6 can become chronically active and has been associated not only with secondary graft failure but pure red cell aplasia as well
CMV reactivation in the post HSCT period can also be accompanied by an acute syndrome manifested by fever myalgia and suppressed marrow function Leukopenia at the start of CMV therapy has been associated with a poor response to anti-viral therapy and is a risk factor for progression of CMV viremia to CMV disease While the most serious manifestations of CMV disease are related to pulmonary and enteral infections CMV-induced marrow suppression and marrow failure has been described with identification of specific genotypes of CMV highly associated with mortality from pancytopenia Because CMV and the treatment for CMV can both be associated with post HSCT cytopenias it is often difficult to distinguish which of the two is the major etiological factor
Although the pathophysiology is unclear persistent cytopenias post HSCT have also been associated with acute and chronic GVHD bacterial and fungal infections and impaired hepatic and renal function Because failure of hematopoietic recovery after HSCT is associated with compromised patient survival this protocol was developed to provide patients with persistent cytopenias post HSCT a boost of their original donors HSCs to improve peripheral blood counts
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2012-35 | OTHER | CCRRC | None |